Effektivnaya i gibkaya farmakoterapiya ozhireniya segodnya - zalog uspeshnoy profilaktiki sakharnogo diabeta 2 tipa v budushchem
https://doi.org/10.14341/2072-0351-5862
Abstract
Ожирение является не только важнейшей медицинской, но и социально-экономической проблемой современного общества. Так, экономические затраты в связи с лечением ожирения и его осложнений очень велики: в развитых странах мира расходы на лечение ожирения и сопутствующих ему заболеваний составляют 8?10% от всех затрат на здравоохранение. Снижение
массы тела позволяет существенно уменьшить клинические проявления, улучшить контроль и повысить эффективность терапии коморбидных заболеваний. Лечение ожирения ? достаточно сложная задача, поскольку это хроническое заболевание, требующее длительного, систематического наблюдения и лечения.
массы тела позволяет существенно уменьшить клинические проявления, улучшить контроль и повысить эффективность терапии коморбидных заболеваний. Лечение ожирения ? достаточно сложная задача, поскольку это хроническое заболевание, требующее длительного, систематического наблюдения и лечения.
About the Authors
Elena Valer'evna Biryukova
МГМСУ, Москва
N V Markina
МГМСУ, Москва
M A Garbuzova
МГМСУ, Москва
References
1. Alberti G., Zimmet P., Shaw J. Type 2 Diabetes in the Young: The Evolving Epidemic: The International Diabetes Federation Consensus Workshop. // Diabetes Care 2004; 27: 1798-1811
2. Arterburn D.E., Crane P.K., Veenstra D.L. The efficacy and safety of sibutramine for weight loss: a systematic review. // Arch Intern Med. 2004;164 (9):994-1003
3. Appolinario JC, Bacaltchuk J, Sichieri R. et al. A randomized, doubleblind, placebo-controlled study of sibutramine in the treatment of bingeeating disorder. // Archives of General Psychiatry. 2003;60(11):1109-16.
4. Berkowitz R.I, Fujioka K., Daniels S.R. et al // Effects of sibutramine treatment in obese adolescents.// Ann Int Med 2006; 145:81-90
5. Bjorntorp P. Obesity .// Lancet.-1997;350:423-6.
6. Calle E. E., Rodriguez C., Walker-Thurmond K., Thun M. J. Overweight, Obesity, and Mortality from Cancer in a Prospectively Studied Cohort of U.S. Adults // N Engl J Med 2003; 348 (17):1625-1638
7. Cuellar G.E.M., Ruiz A.M., Monsalve M.C.R. et al. Six-month treatment of obesity with sibutramine 15 mg: a double-blind, placebo-controlled monocenter clinical trial in a Hispanic population. // Obes Res. 2000; 8:71-82.
8. Desideri G, De Simone M, Iughetti L. et al: Early activation of vascular endothelial cells and platelets in obese children. // J Clin Endocrinol Metabol 2005;90-6:3145-52
9. Dujovne C.A., Zavoral J.H., Rowe E., Mendel C.M. Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebocontrolled study in 322 overweight and obese patients with dyslipidemia. // Am Heart J 2001;142,489-497
10. Faria A.N., Ribeiro Filho F.F., Lerario D.D. et al. // Effects of sibutramine on the treatment of obesity in patients with arterial hypertension. // Arq Bras Cardiol. 2002; 78:172-180.
11. Finer N., Bloom S.R., Frost G.S. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double- blind, placebo-controlled study.// Diabetes Obes Metab. 2000;2(2):105-12
12. Fujioka K., Seaton T.B., Rowe E. et al. Weight loss with sibutramine improves glycemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. // Diabetes Obes Metab 2000; 2:175-187.
13. Gokcel A, Gumurdulu Y, Karakose H, et al. Evaluation of the safety and efficacy of sibutramine, orlistat, and metformin in the treatment of obesity. // Diabetes, Obesity and Metabolism. 2002; 4: 49-55.
14. Hainer V., Kabrnova K., Aldhoon B. et al. Serotonin and Norepinephrine Reuptake Inhibition and Eating Behavior.// Ann. N.Y. Acad. Sci. 2006; 1083(1): 252 - 269.
15. Hansen D., Astrub A., Toubro S. et al. Prediction of weight loss and maintenance during 2 years of treatment by sibutramine in obesity: results from the European multi-center STORM trial. // Int G Obes 2002;25:496-501.
16. Luque C.A, Rey J.A. The discovery and status of sibutramine as an anti-obesity drug. // Eur J Pharmacol 2002; 440,119-128
17. Manson J.E, Willett W.C., Stampfer M.J. et al. Body weight and mortality among women. // N Engl J Med 1995; 333:677-685
18. McNulty S.J., Ur E., Williams G. Multicenter Sibutramine Study Group. A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin. // Diabetes Care.2003; 26:125 -131
19. McMahon F.G., Weinstein S.P., Rowe E. et al. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. // J Hum Hypertens 2002; 16: 5-11.
20. Phelan S., Wadden T.F. Combining Behavioral and Pharmacological Treatments for Obesity. // Obesity 2002; 10(6): 560 - 574.
21. Rahmouni K., Correia M.L.G., Haynes W.G. et al. Obesity-associated hypertension // Hypertension 2005; 45: 9-14
22. Smith I.G., Goulder M.A. Randomized placebo-controlled trial of longterm treatment with sibutramine in mild to moderate obesity. // J Fam Pract. 2001; 50:505-12.
23. Sramek J.J., Leibowitz M.T., Weinstein S.P. et al. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double- blind, randomised trial. // J Hum Hypertens 2002; 16:13-19
24. Tounian P., Aggoun Y., Dubern B., et al: Presence of increased stiffness of the common carotid artery and endothelial dysfunction in severely obese children: a prospective study.// Lancet 2001; 385:1400-04
25. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). // Lancet 1998; 352:837-853
26. Van Gaal et al. Endocrinologia Metabolizmo& Nutricao. Sep 2006; 15(5):270.Abst.CO 30
27. Walsh KM, Leen E, Lean ME. The effect of sibutramine on resting energy expenditure and adrenaline-induced thermogenesis in obese females. // International Journal of Obesity & Related Metabolic Disorders. 1999; 23: 1009-1015.
28. Wolf A.M., Colditz G.A. Current estimates of the economic cost of obesity in the United States. // Obes Res.1998; 6:97-106.
29. Wooltorton E. Obesity drug sibutramine (Meridia): hypertension and cardiac arrhythmias. // CMAJ 2002; 166 (10):1307-1308.
30. Yanovski S.Z., Yanovski J.A. Obesity. // NEJM 2002; 346:591-602.
Review
For citations:
Biryukova E.V., Markina N.V., Garbuzova M.A. Effektivnaya i gibkaya farmakoterapiya ozhireniya segodnya - zalog uspeshnoy profilaktiki sakharnogo diabeta 2 tipa v budushchem. Diabetes mellitus. 2007;10(4):23-28. (In Russ.) https://doi.org/10.14341/2072-0351-5862
Views:
2873
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
